JP2022534979A - 置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法 - Google Patents
置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法 Download PDFInfo
- Publication number
- JP2022534979A JP2022534979A JP2021570866A JP2021570866A JP2022534979A JP 2022534979 A JP2022534979 A JP 2022534979A JP 2021570866 A JP2021570866 A JP 2021570866A JP 2021570866 A JP2021570866 A JP 2021570866A JP 2022534979 A JP2022534979 A JP 2022534979A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- unsubstituted
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 239000000203 mixture Chemical class 0.000 title abstract description 169
- WNOMNVMWZAPUOQ-UHFFFAOYSA-N 1-oxo-2,3-dihydroisoindole-5-carboxamide Chemical class NC(=O)C1=CC=C2C(=O)NCC2=C1 WNOMNVMWZAPUOQ-UHFFFAOYSA-N 0.000 title abstract description 7
- 238000011282 treatment Methods 0.000 title description 33
- 150000001875 compounds Chemical class 0.000 claims description 256
- -1 n - propyl Chemical group 0.000 claims description 152
- 125000000217 alkyl group Chemical group 0.000 claims description 81
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 76
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 74
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 40
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 claims description 38
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 claims description 38
- 239000002904 solvent Substances 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 229910052731 fluorine Inorganic materials 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 15
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000005936 piperidyl group Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 claims description 6
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 4
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 238000011443 conventional therapy Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- LZCVVMQABORALM-UHFFFAOYSA-N spiro[2.5]octyl Chemical group [CH]1CC11CCCCC1 LZCVVMQABORALM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 2
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- AQIAIZBHFAKICS-UHFFFAOYSA-N methylaminomethyl Chemical compound [CH2]NC AQIAIZBHFAKICS-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 90
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 87
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 83
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 82
- 230000002829 reductive effect Effects 0.000 description 56
- 239000000243 solution Substances 0.000 description 55
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- 238000010561 standard procedure Methods 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 239000002552 dosage form Substances 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 239000007821 HATU Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 19
- 230000037396 body weight Effects 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- DZACPFIVEGYGNL-UHFFFAOYSA-N 2,3-dihydro-1h-isoindole-5-carboxamide Chemical compound NC(=O)C1=CC=C2CNCC2=C1 DZACPFIVEGYGNL-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- BMBNTSFSFRJPGO-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindole-5-carboxylic acid Chemical compound OC(=O)c1ccc2C(=O)N(Cc2c1)C1CCC(=O)NC1=O BMBNTSFSFRJPGO-UHFFFAOYSA-N 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 229910002091 carbon monoxide Inorganic materials 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 12
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 12
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 11
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 11
- 235000019270 ammonium chloride Nutrition 0.000 description 11
- 229960000684 cytarabine Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229910052740 iodine Inorganic materials 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000000155 isotopic effect Effects 0.000 description 9
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 6
- 229940092714 benzenesulfonic acid Drugs 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000007822 coupling agent Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 238000011476 stem cell transplantation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DGAWFEDONPXNNP-WMLDXEAASA-N ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O Chemical compound ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O DGAWFEDONPXNNP-WMLDXEAASA-N 0.000 description 5
- NTNBVLXHHRWOFY-UHUGOGIASA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)=O)=O NTNBVLXHHRWOFY-UHUGOGIASA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 238000005415 bioluminescence Methods 0.000 description 5
- 230000029918 bioluminescence Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 229960001183 venetoclax Drugs 0.000 description 5
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 5
- BMJQOPDJQFLGFV-OGFXRTJISA-N (1r)-2,2,2-trifluoro-1-(4-fluorophenyl)ethanamine;hydrochloride Chemical compound Cl.FC(F)(F)[C@H](N)C1=CC=C(F)C=C1 BMJQOPDJQFLGFV-OGFXRTJISA-N 0.000 description 4
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- AWKMPKHZSVTSPT-GRFAERAESA-N CC(C)(C)[S@](=O)/N=C/C1=C(C=CC=C1)N1CCOCC1 Chemical compound CC(C)(C)[S@](=O)/N=C/C1=C(C=CC=C1)N1CCOCC1 AWKMPKHZSVTSPT-GRFAERAESA-N 0.000 description 4
- NFDFHAWYPXBYLZ-FYZOBXCZSA-N Cl.ClC=1C(=NC=C(C=1)Cl)[C@H](C(F)(F)F)N Chemical compound Cl.ClC=1C(=NC=C(C=1)Cl)[C@H](C(F)(F)F)N NFDFHAWYPXBYLZ-FYZOBXCZSA-N 0.000 description 4
- PONANWTWVFWRQJ-FYZOBXCZSA-N Cl.ClC=1C=C(C(=NC=1)[C@H](C(F)(F)F)N)F Chemical compound Cl.ClC=1C=C(C(=NC=1)[C@H](C(F)(F)F)N)F PONANWTWVFWRQJ-FYZOBXCZSA-N 0.000 description 4
- PQKHKQILMJHXJM-SPSFWMDKSA-N ClC=1C(=NC=C(C=1)CN(C)C)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C Chemical compound ClC=1C(=NC=C(C=1)CN(C)C)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C PQKHKQILMJHXJM-SPSFWMDKSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- VBENMCSASBBBCR-ZDUSSCGKSA-N NC([C@H](CCC(=O)OC(C)(C)C)N1C(C2=CC=C(C=C2C1)C(=O)O)=O)=O Chemical compound NC([C@H](CCC(=O)OC(C)(C)C)N1C(C2=CC=C(C=C2C1)C(=O)O)=O)=O VBENMCSASBBBCR-ZDUSSCGKSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007596 consolidation process Methods 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 238000009093 first-line therapy Methods 0.000 description 4
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 4
- 229950006304 gilteritinib Drugs 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 238000011301 standard therapy Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- CQZMNGPRQBZYSO-FYZOBXCZSA-N (1r)-2,2,2-trifluoro-1-pyridin-2-ylethanamine;hydrochloride Chemical compound Cl.FC(F)(F)[C@H](N)C1=CC=CC=N1 CQZMNGPRQBZYSO-FYZOBXCZSA-N 0.000 description 3
- BORKUOMEZNUZAA-NRUITVPNSA-N (NE,S)-N-[(4-fluorophenyl)methylidene]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](=O)\N=C\c1ccc(F)cc1 BORKUOMEZNUZAA-NRUITVPNSA-N 0.000 description 3
- KUCQUPHAVIWWPZ-HNNXBMFYSA-N (S)-N-[(5-chloropyridin-2-yl)methylidene]-2-methylpropane-2-sulfinamide Chemical compound ClC=1C=CC(=NC=1)C=N[S@@](=O)C(C)(C)C KUCQUPHAVIWWPZ-HNNXBMFYSA-N 0.000 description 3
- AIPSJOUYSQXOGI-XYOKQWHBSA-N (ne)-2-methyl-n-(pyridin-2-ylmethylidene)propane-2-sulfinamide Chemical compound CC(C)(C)S(=O)\N=C\C1=CC=CC=N1 AIPSJOUYSQXOGI-XYOKQWHBSA-N 0.000 description 3
- BTUUNHWXZRCLLJ-NTUHNPAUSA-N (ne)-n-[(3-chloropyridin-2-yl)methylidene]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)S(=O)\N=C\C1=NC=CC=C1Cl BTUUNHWXZRCLLJ-NTUHNPAUSA-N 0.000 description 3
- KANGWGJLFQRLOW-COSNYCCFSA-N (ne)-n-[(3-fluoropyridin-2-yl)methylidene]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](=O)\N=C\C1=NC=CC=C1F KANGWGJLFQRLOW-COSNYCCFSA-N 0.000 description 3
- PGUSPUZMIIACHQ-UHFFFAOYSA-N 2-cyclopropyloxybenzaldehyde Chemical compound O=CC1=CC=CC=C1OC1CC1 PGUSPUZMIIACHQ-UHFFFAOYSA-N 0.000 description 3
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- XWPYNAKKDOJLGJ-UHFFFAOYSA-N BrC=1C(=C(CNC2C(NC(CC2)=O)=O)C(=CC=1)Br)Cl Chemical compound BrC=1C(=C(CNC2C(NC(CC2)=O)=O)C(=CC=1)Br)Cl XWPYNAKKDOJLGJ-UHFFFAOYSA-N 0.000 description 3
- WNPPRENXMUPRQX-UHFFFAOYSA-N BrC=1C(=C(CNC2C(NC(CC2)=O)=O)C(=CC=1)Br)F Chemical compound BrC=1C(=C(CNC2C(NC(CC2)=O)=O)C(=CC=1)Br)F WNPPRENXMUPRQX-UHFFFAOYSA-N 0.000 description 3
- NKPFMNDJYRCPNN-BDPMCISCSA-N C1(CC1)OC1=C(C=CC=C1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound C1(CC1)OC1=C(C=CC=C1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O NKPFMNDJYRCPNN-BDPMCISCSA-N 0.000 description 3
- BHAQCDKTMNCPQC-DMZKTXOQSA-N C1(CC1)OC1=C(C=CC=C1)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C Chemical compound C1(CC1)OC1=C(C=CC=C1)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C BHAQCDKTMNCPQC-DMZKTXOQSA-N 0.000 description 3
- CJSXQCHLZDPZFO-YJJYDOSJSA-N C1(CCCCC1)[C@@H](C)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound C1(CCCCC1)[C@@H](C)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O CJSXQCHLZDPZFO-YJJYDOSJSA-N 0.000 description 3
- CJSXQCHLZDPZFO-FVRDMJKUSA-N C1(CCCCC1)[C@H](C)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound C1(CCCCC1)[C@H](C)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O CJSXQCHLZDPZFO-FVRDMJKUSA-N 0.000 description 3
- LQSYPZRAACYUKG-DGIBIBHMSA-N CC(C)(C)[S@](=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F Chemical compound CC(C)(C)[S@](=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F LQSYPZRAACYUKG-DGIBIBHMSA-N 0.000 description 3
- FPQOHIMBWICZHW-LZVRBXCZSA-N CC(C)(C)[S@](=O)N[C@@H](C(F)(F)F)C1=NC=CC=C1 Chemical compound CC(C)(C)[S@](=O)N[C@@H](C(F)(F)F)C1=NC=CC=C1 FPQOHIMBWICZHW-LZVRBXCZSA-N 0.000 description 3
- BXDZLUZHWFEAIV-HOGDKLEQSA-N CC(C)(C)[S@](=O)N[C@@H](C(F)(F)F)C1=NC=CC=C1F Chemical compound CC(C)(C)[S@](=O)N[C@@H](C(F)(F)F)C1=NC=CC=C1F BXDZLUZHWFEAIV-HOGDKLEQSA-N 0.000 description 3
- ZEGORPOULPAQGI-HNCPQSOCSA-N Cl.C1(CC1)OC1=C(C=CC=C1)[C@H](C(F)(F)F)N Chemical compound Cl.C1(CC1)OC1=C(C=CC=C1)[C@H](C(F)(F)F)N ZEGORPOULPAQGI-HNCPQSOCSA-N 0.000 description 3
- YRLWHXAJCUOSGI-KLQYNRQASA-N Cl.Cl.ClC=1C(=NC=C(C=1)CN(C)C)[C@H](C(F)(F)F)N Chemical compound Cl.Cl.ClC=1C(=NC=C(C=1)CN(C)C)[C@H](C(F)(F)F)N YRLWHXAJCUOSGI-KLQYNRQASA-N 0.000 description 3
- HLVOWSZLHIXNPD-UHFFFAOYSA-N Cl.ClC=1C(=NC=C(C=1)CN(C)C)C(=O)O Chemical compound Cl.ClC=1C(=NC=C(C=1)CN(C)C)C(=O)O HLVOWSZLHIXNPD-UHFFFAOYSA-N 0.000 description 3
- COVQQZHORDNRPO-FYZOBXCZSA-N Cl.ClC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)N Chemical compound Cl.ClC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)N COVQQZHORDNRPO-FYZOBXCZSA-N 0.000 description 3
- GFJXDXGNLCJUQU-FYZOBXCZSA-N Cl.ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)N Chemical compound Cl.ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)N GFJXDXGNLCJUQU-FYZOBXCZSA-N 0.000 description 3
- HTPLKQGHTDEACR-FYZOBXCZSA-N Cl.ClC=1C=CC(=NC=1)[C@H](C(F)(F)F)N Chemical compound Cl.ClC=1C=CC(=NC=1)[C@H](C(F)(F)F)N HTPLKQGHTDEACR-FYZOBXCZSA-N 0.000 description 3
- OZGSHYLLGPJPMO-RFVHGSKJSA-N Cl.FC([C@H](N)C1=C(C=CC=C1)N1CCOCC1)(F)F Chemical compound Cl.FC([C@H](N)C1=C(C=CC=C1)N1CCOCC1)(F)F OZGSHYLLGPJPMO-RFVHGSKJSA-N 0.000 description 3
- MFHLYQRXSHJHKU-FYZOBXCZSA-N Cl.FC([C@H](N)C1=NC=CC=C1F)(F)F Chemical compound Cl.FC([C@H](N)C1=NC=CC=C1F)(F)F MFHLYQRXSHJHKU-FYZOBXCZSA-N 0.000 description 3
- RJJJTIQEVLHSQC-FYZOBXCZSA-N Cl.FC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)N Chemical compound Cl.FC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)N RJJJTIQEVLHSQC-FYZOBXCZSA-N 0.000 description 3
- STZAOFQSHQVQRI-UHFFFAOYSA-N ClC1=C2CN(C(C2=CC=C1C(=O)O)=O)C1C(NC(CC1)=O)=O Chemical compound ClC1=C2CN(C(C2=CC=C1C(=O)O)=O)C1C(NC(CC1)=O)=O STZAOFQSHQVQRI-UHFFFAOYSA-N 0.000 description 3
- PFDTVLBAYIWZPT-UHFFFAOYSA-N ClC=1C(=NC=C(C=1)CN(C)C)C#N Chemical compound ClC=1C(=NC=C(C=1)CN(C)C)C#N PFDTVLBAYIWZPT-UHFFFAOYSA-N 0.000 description 3
- XZYPSRCALGHJIG-UHFFFAOYSA-N ClC=1C(=NC=C(C=1)CN(C)C)C(=O)N(C)OC Chemical compound ClC=1C(=NC=C(C=1)CN(C)C)C(=O)N(C)OC XZYPSRCALGHJIG-UHFFFAOYSA-N 0.000 description 3
- OUDRQHKDMUGBAM-UHFFFAOYSA-N ClC=1C(=NC=C(C=1)CN(C)C)C=O Chemical compound ClC=1C(=NC=C(C=1)CN(C)C)C=O OUDRQHKDMUGBAM-UHFFFAOYSA-N 0.000 description 3
- MFYOACSKKFCZTB-WMLDXEAASA-N ClC=1C(=NC=C(C=1)Cl)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O Chemical compound ClC=1C(=NC=C(C=1)Cl)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O MFYOACSKKFCZTB-WMLDXEAASA-N 0.000 description 3
- JFINPPOEUKYXQY-YBYGRFCBSA-N ClC=1C(=NC=C(C=1)Cl)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C Chemical compound ClC=1C(=NC=C(C=1)Cl)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C JFINPPOEUKYXQY-YBYGRFCBSA-N 0.000 description 3
- IYLAORVENVWFPR-CQMBDMNQSA-N ClC=1C(=NC=C(C=1)Cl)\C=N\[S@@](=O)C(C)(C)C Chemical compound ClC=1C(=NC=C(C=1)Cl)\C=N\[S@@](=O)C(C)(C)C IYLAORVENVWFPR-CQMBDMNQSA-N 0.000 description 3
- KEATWBIFZMGDPC-YBYGRFCBSA-N ClC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C Chemical compound ClC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C KEATWBIFZMGDPC-YBYGRFCBSA-N 0.000 description 3
- PXCOYVKMIIJZGF-CQMBDMNQSA-N ClC=1C(=NC=C(C=1)F)\C=N\[S@@](=O)C(C)(C)C Chemical compound ClC=1C(=NC=C(C=1)F)\C=N\[S@@](=O)C(C)(C)C PXCOYVKMIIJZGF-CQMBDMNQSA-N 0.000 description 3
- DGAWFEDONPXNNP-RHSMWYFYSA-N ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)[C@H]1C(NC(CC1)=O)=O Chemical compound ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)[C@H]1C(NC(CC1)=O)=O DGAWFEDONPXNNP-RHSMWYFYSA-N 0.000 description 3
- QYQLGEUTYLLSGG-HOGDKLEQSA-N ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C Chemical compound ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C QYQLGEUTYLLSGG-HOGDKLEQSA-N 0.000 description 3
- GNWXSWVFOQQWGW-FBMWCMRBSA-N ClC=1C=C(C(=NC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)F Chemical compound ClC=1C=C(C(=NC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)F GNWXSWVFOQQWGW-FBMWCMRBSA-N 0.000 description 3
- GNWXSWVFOQQWGW-WMLDXEAASA-N ClC=1C=C(C(=NC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)F Chemical compound ClC=1C=C(C(=NC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)F GNWXSWVFOQQWGW-WMLDXEAASA-N 0.000 description 3
- JQIPEWSDAMWHNV-YBYGRFCBSA-N ClC=1C=C(C(=NC=1)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C)F Chemical compound ClC=1C=C(C(=NC=1)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C)F JQIPEWSDAMWHNV-YBYGRFCBSA-N 0.000 description 3
- QCZAORCHAGFFSA-CQMBDMNQSA-N ClC=1C=C(C(=NC=1)\C=N\[S@@](=O)C(C)(C)C)F Chemical compound ClC=1C=C(C(=NC=1)\C=N\[S@@](=O)C(C)(C)C)F QCZAORCHAGFFSA-CQMBDMNQSA-N 0.000 description 3
- RMEJKLDQKVMIRN-HOGDKLEQSA-N ClC=1C=CC(=NC=1)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C Chemical compound ClC=1C=CC(=NC=1)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C RMEJKLDQKVMIRN-HOGDKLEQSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- XYHNNLAEOOZQLD-FBMWCMRBSA-N FC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound FC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O XYHNNLAEOOZQLD-FBMWCMRBSA-N 0.000 description 3
- FDPOCTAKWACGPL-YBYGRFCBSA-N FC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C Chemical compound FC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)N[S@@](=O)C(C)(C)C FDPOCTAKWACGPL-YBYGRFCBSA-N 0.000 description 3
- CVUKEPFCFYQXLM-CQMBDMNQSA-N FC=1C(=NC=C(C=1)F)\C=N\[S@@](=O)C(C)(C)C Chemical compound FC=1C(=NC=C(C=1)F)\C=N\[S@@](=O)C(C)(C)C CVUKEPFCFYQXLM-CQMBDMNQSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OBCYSDKGKQWABZ-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1)C(=O)O)F)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1)C(=O)O)F)=O)=O OBCYSDKGKQWABZ-UHFFFAOYSA-N 0.000 description 3
- KZAHAOQJEYWJLV-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=C(C(=C2C1)F)C(=O)O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C(=C2C1)F)C(=O)O)=O)=O KZAHAOQJEYWJLV-UHFFFAOYSA-N 0.000 description 3
- HQOVIOPUBIJQJR-QWAKEFERSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(C)C)C1=CC=CC=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(C)C)C1=CC=CC=C1)=O)=O HQOVIOPUBIJQJR-QWAKEFERSA-N 0.000 description 3
- QNHSYWMURJOOIJ-UHUGOGIASA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F)=O)=O Chemical class O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F)=O)=O QNHSYWMURJOOIJ-UHUGOGIASA-N 0.000 description 3
- HGCMZAYEVIKTTB-FVRDMJKUSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C)C1=CC=CC=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C)C1=CC=CC=C1)=O)=O HGCMZAYEVIKTTB-FVRDMJKUSA-N 0.000 description 3
- CGUNHEGHUSMCLJ-OYKVQYDMSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](CC)C1=CC=CC=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](CC)C1=CC=CC=C1)=O)=O CGUNHEGHUSMCLJ-OYKVQYDMSA-N 0.000 description 3
- NTNBVLXHHRWOFY-FUHWJXTLSA-N O=C1NC(CC[C@@H]1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)=O)=O Chemical compound O=C1NC(CC[C@@H]1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)=O)=O NTNBVLXHHRWOFY-FUHWJXTLSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000009108 consolidation therapy Methods 0.000 description 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000005241 heteroarylamino group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000011368 intensive chemotherapy Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- PJAVHBBCXQIYII-FXAWDEMLSA-N tert-butyl (4S)-5-amino-4-[6-[[(1R)-1-(5-chloro-3-fluoropyridin-2-yl)-2,2,2-trifluoroethyl]carbamoyl]-3-oxo-1H-isoindol-2-yl]-5-oxopentanoate Chemical compound NC([C@H](CCC(=O)OC(C)(C)C)N1C(C2=CC=C(C=C2C1)C(N[C@@H](C(F)(F)F)C1=NC=C(C=C1F)Cl)=O)=O)=O PJAVHBBCXQIYII-FXAWDEMLSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 238000001851 vibrational circular dichroism spectroscopy Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- DZCAUMADOBDJJH-SSDOTTSWSA-N (1r)-2,2,2-trifluoro-1-phenylethanamine Chemical compound FC(F)(F)[C@H](N)C1=CC=CC=C1 DZCAUMADOBDJJH-SSDOTTSWSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 description 2
- JBSWVRQPSOANFC-UHFFFAOYSA-N 3-(6-bromo-5-fluoro-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound BrC=1C=C2CN(C(C2=CC=1F)=O)C1C(NC(CC1)=O)=O JBSWVRQPSOANFC-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LCVQEFLXXVYPIR-KAPURRDVSA-N C1(CC1)OC1=C(\C=N\[S@@](=O)C(C)(C)C)C=CC=C1 Chemical compound C1(CC1)OC1=C(\C=N\[S@@](=O)C(C)(C)C)C=CC=C1 LCVQEFLXXVYPIR-KAPURRDVSA-N 0.000 description 2
- LUCUJFDHUXTFMQ-UHUGOGIASA-N C1(CCCCC1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound C1(CCCCC1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O LUCUJFDHUXTFMQ-UHUGOGIASA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- WRIUFNURRGQZAU-NJPRBYKHSA-N Cl.ClC=1C(=NC=C(C=1)CN(C)C)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound Cl.ClC=1C(=NC=C(C=1)CN(C)C)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O WRIUFNURRGQZAU-NJPRBYKHSA-N 0.000 description 2
- FECYTIOMZGQKJN-NXNKFBBFSA-N ClC=1C(=NC=C(C=1)CN(C)C)\C=N\[S@@](=O)C(C)(C)C Chemical compound ClC=1C(=NC=C(C=1)CN(C)C)\C=N\[S@@](=O)C(C)(C)C FECYTIOMZGQKJN-NXNKFBBFSA-N 0.000 description 2
- MFYOACSKKFCZTB-FBMWCMRBSA-N ClC=1C(=NC=C(C=1)Cl)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound ClC=1C(=NC=C(C=1)Cl)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O MFYOACSKKFCZTB-FBMWCMRBSA-N 0.000 description 2
- CVBMZONJIWZEFY-FBMWCMRBSA-N ClC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound ClC=1C(=NC=C(C=1)F)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O CVBMZONJIWZEFY-FBMWCMRBSA-N 0.000 description 2
- DGAWFEDONPXNNP-FBMWCMRBSA-N ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound ClC=1C(=NC=CC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O DGAWFEDONPXNNP-FBMWCMRBSA-N 0.000 description 2
- RHXHOEOGSJZRBX-OMOCHNIRSA-N ClC=1C=CC(=NC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O Chemical compound ClC=1C=CC(=NC=1)[C@H](C(F)(F)F)NC(=O)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O RHXHOEOGSJZRBX-OMOCHNIRSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- ADHQBYZHDPKULA-UHUGOGIASA-N O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)F)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)F)=O)=O ADHQBYZHDPKULA-UHUGOGIASA-N 0.000 description 2
- AEBVRRMZVOEOAZ-KPMSDPLLSA-N O=C1NC(CCC1N1C(C2=CC=C(C(=C2C1)F)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C(=C2C1)F)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)=O)=O AEBVRRMZVOEOAZ-KPMSDPLLSA-N 0.000 description 2
- MKSIGNYBDFIXTO-LWMIZPGFSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=C(C=CC=C1)N1CCOCC1)=O)=O Chemical class O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=C(C=CC=C1)N1CCOCC1)=O)=O MKSIGNYBDFIXTO-LWMIZPGFSA-N 0.000 description 2
- IJBFRYHZKGDJCI-OMOCHNIRSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=NC=CC=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=NC=CC=C1)=O)=O IJBFRYHZKGDJCI-OMOCHNIRSA-N 0.000 description 2
- SVBUMCHRSPMUCV-FBMWCMRBSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=NC=CC=C1F)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=NC=CC=C1F)=O)=O SVBUMCHRSPMUCV-FBMWCMRBSA-N 0.000 description 2
- MBXYWRNKILOKFU-OMOCHNIRSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C=1C=NC=CC=1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C=1C=NC=CC=1)=O)=O MBXYWRNKILOKFU-OMOCHNIRSA-N 0.000 description 2
- VRMWFDHIYNOMOM-ZENAZSQFSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](CC(F)(F)F)C1=CC=CC=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](CC(F)(F)F)C1=CC=CC=C1)=O)=O VRMWFDHIYNOMOM-ZENAZSQFSA-N 0.000 description 2
- QNHSYWMURJOOIJ-SJLPKXTDSA-N O=C1NC(CC[C@H]1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F)=O)=O Chemical compound O=C1NC(CC[C@H]1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F)=O)=O QNHSYWMURJOOIJ-SJLPKXTDSA-N 0.000 description 2
- NTNBVLXHHRWOFY-SJLPKXTDSA-N O=C1NC(CC[C@H]1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)=O)=O Chemical compound O=C1NC(CC[C@H]1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=CC=C1)=O)=O NTNBVLXHHRWOFY-SJLPKXTDSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 101150076546 csnk1a1 gene Proteins 0.000 description 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- RSJBEKXKEUQLER-UHFFFAOYSA-N dicyclohexyl(3-dicyclohexylphosphanylpropyl)phosphane Chemical compound C1CCCCC1P(C1CCCCC1)CCCP(C1CCCCC1)C1CCCCC1 RSJBEKXKEUQLER-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 125000005883 dithianyl group Chemical group 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- XGZNHFPFJRZBBT-UHFFFAOYSA-N ethanol;titanium Chemical compound [Ti].CCO.CCO.CCO.CCO XGZNHFPFJRZBBT-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- SFNSLLSYNZWZQG-VQIMIIECSA-N glasdegib Chemical compound N([C@@H]1CCN([C@H](C1)C=1NC2=CC=CC=C2N=1)C)C(=O)NC1=CC=C(C#N)C=C1 SFNSLLSYNZWZQG-VQIMIIECSA-N 0.000 description 2
- 229950003566 glasdegib Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- WIJZXSAJMHAVGX-DHLKQENFSA-N ivosidenib Chemical compound FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229950010895 midostaurin Drugs 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-OUBTZVSYSA-N nitrogen-15 Chemical compound [15N] QJGQUHMNIGDVPM-OUBTZVSYSA-N 0.000 description 2
- CMUOJBJRZUHRMU-UHFFFAOYSA-N nitrourea Chemical compound NC(=O)N[N+]([O-])=O CMUOJBJRZUHRMU-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- VRPBVRRWDBCBGF-FXAWDEMLSA-N tert-butyl (4S)-5-amino-4-[6-[[(1R)-1-(3,5-dichloropyridin-2-yl)-2,2,2-trifluoroethyl]carbamoyl]-3-oxo-1H-isoindol-2-yl]-5-oxopentanoate Chemical compound NC([C@H](CCC(=O)OC(C)(C)C)N1C(C2=CC=C(C=C2C1)C(N[C@@H](C(F)(F)F)C1=NC=C(C=C1Cl)Cl)=O)=O)=O VRPBVRRWDBCBGF-FXAWDEMLSA-N 0.000 description 2
- FMQBLEXZQIIDJB-FXAWDEMLSA-N tert-butyl (4S)-5-amino-4-[6-[[(1R)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl]carbamoyl]-3-oxo-1H-isoindol-2-yl]-5-oxopentanoate Chemical compound NC([C@H](CCC(=O)OC(C)(C)C)N1C(C2=CC=C(C=C2C1)C(N[C@@H](C(F)(F)F)C1=NC=CC=C1Cl)=O)=O)=O FMQBLEXZQIIDJB-FXAWDEMLSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NLDVAGWIUPSGQC-FYZOBXCZSA-N (1R)-2,2,2-trifluoro-1-pyridin-3-ylethanamine hydrochloride Chemical compound Cl.N[C@H](c1cccnc1)C(F)(F)F NLDVAGWIUPSGQC-FYZOBXCZSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- CERGJGMILXAJNN-OGFXRTJISA-N (1r)-1-cyclohexyl-2,2,2-trifluoroethanamine;hydrochloride Chemical compound Cl.FC(F)(F)[C@H](N)C1CCCCC1 CERGJGMILXAJNN-OGFXRTJISA-N 0.000 description 1
- XBWOPGDJMAJJDG-SSDOTTSWSA-N (1r)-1-cyclohexylethanamine Chemical compound C[C@@H](N)C1CCCCC1 XBWOPGDJMAJJDG-SSDOTTSWSA-N 0.000 description 1
- XBWOPGDJMAJJDG-ZETCQYMHSA-N (1s)-1-cyclohexylethanamine Chemical compound C[C@H](N)C1CCCCC1 XBWOPGDJMAJJDG-ZETCQYMHSA-N 0.000 description 1
- AQFLVLHRZFLDDV-VIFPVBQESA-N (1s)-1-phenylpropan-1-amine Chemical compound CC[C@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-VIFPVBQESA-N 0.000 description 1
- LZDSYIZUCSUNKJ-PPHPATTJSA-N (1s)-2-methyl-1-phenylpropan-1-amine;hydrochloride Chemical compound Cl.CC(C)[C@H](N)C1=CC=CC=C1 LZDSYIZUCSUNKJ-PPHPATTJSA-N 0.000 description 1
- KBXXAXKUJGFVHY-QMMMGPOBSA-N (1s)-3,3,3-trifluoro-1-phenylpropan-1-amine Chemical compound FC(F)(F)C[C@H](N)C1=CC=CC=C1 KBXXAXKUJGFVHY-QMMMGPOBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UJOUWHLYTQFUCU-WXXKFALUSA-N (e)-but-2-enedioic acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide Chemical compound OC(=O)\C=C\C(O)=O.N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1.N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 UJOUWHLYTQFUCU-WXXKFALUSA-N 0.000 description 1
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
- LCGFVWKNXLRFIF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1=CC=C2CC(N)CCC2=C1 LCGFVWKNXLRFIF-UHFFFAOYSA-N 0.000 description 1
- VJCVKWFBWAVYOC-UIXXXISESA-N 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea (Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N VJCVKWFBWAVYOC-UIXXXISESA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- DZTLKUKANGQSRN-UHFFFAOYSA-N 2,3-dihydro-1h-indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NCCC2=C1 DZTLKUKANGQSRN-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- DYQOVHGBRUEOMB-UHFFFAOYSA-N 3,5-dichloropyridine-2-carbaldehyde Chemical compound ClC1=CN=C(C=O)C(Cl)=C1 DYQOVHGBRUEOMB-UHFFFAOYSA-N 0.000 description 1
- LNBLQSIETHAQMW-UHFFFAOYSA-N 3,5-difluoropyridine-2-carbaldehyde Chemical compound FC1=CN=C(C=O)C(F)=C1 LNBLQSIETHAQMW-UHFFFAOYSA-N 0.000 description 1
- IWLKVQWSDXDHAW-UHFFFAOYSA-N 3,6-dibromo-2-fluorobenzaldehyde Chemical compound FC1=C(Br)C=CC(Br)=C1C=O IWLKVQWSDXDHAW-UHFFFAOYSA-N 0.000 description 1
- WENKGSGGXGQHSH-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical class C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O WENKGSGGXGQHSH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LUSJPWDOJBZYAN-UHFFFAOYSA-N 3-chloro-5-(chloromethyl)pyridine-2-carbonitrile Chemical compound ClCC1=CN=C(C#N)C(Cl)=C1 LUSJPWDOJBZYAN-UHFFFAOYSA-N 0.000 description 1
- AEBPZQQCUYFFJL-UHFFFAOYSA-N 3-chloro-5-fluoropyridine-2-carbaldehyde Chemical compound FC1=CN=C(C=O)C(Cl)=C1 AEBPZQQCUYFFJL-UHFFFAOYSA-N 0.000 description 1
- QXNVCYJXFQPEKQ-UHFFFAOYSA-N 3-chloropyridine-2-carbaldehyde Chemical compound ClC1=CC=CN=C1C=O QXNVCYJXFQPEKQ-UHFFFAOYSA-N 0.000 description 1
- OZIMPUNGBUYCSP-UHFFFAOYSA-N 3-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC=CN=C1C=O OZIMPUNGBUYCSP-UHFFFAOYSA-N 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- YYLBDBOSXXSZQQ-UHFFFAOYSA-N 5-chloropyridine-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)N=C1 YYLBDBOSXXSZQQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- MXNMFKDAFIWMMN-UHFFFAOYSA-N BrC1=C(C(=C(C=C1)Br)Cl)CBr Chemical compound BrC1=C(C(=C(C=C1)Br)Cl)CBr MXNMFKDAFIWMMN-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 102000015367 CRBN Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- VQAYWVORKJIQRJ-KPMSDPLLSA-N ClC1=C2CN(C(C2=CC=C1C(=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F)=O)C1C(NC(CC1)=O)=O Chemical compound ClC1=C2CN(C(C2=CC=C1C(=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F)=O)C1C(NC(CC1)=O)=O VQAYWVORKJIQRJ-KPMSDPLLSA-N 0.000 description 1
- 102000012666 Core Binding Factor Alpha 3 Subunit Human genes 0.000 description 1
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- BMYMCMAHWRKMEP-JTQLQIEISA-N NC([C@H](CCC(=O)O)N1C(C2=CC=C(C=C2C1)C(=O)O)=O)=O Chemical compound NC([C@H](CCC(=O)O)N1C(C2=CC=C(C=C2C1)C(=O)O)=O)=O BMYMCMAHWRKMEP-JTQLQIEISA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QNHSYWMURJOOIJ-FUHWJXTLSA-N O=C1NC(CC[C@@H]1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F)=O)=O Chemical compound O=C1NC(CC[C@@H]1N1C(C2=CC=C(C=C2C1)C(=O)N[C@@H](C(F)(F)F)C1=CC=C(C=C1)F)=O)=O QNHSYWMURJOOIJ-FUHWJXTLSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000033 alkoxyamino group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- QHXLIQMGIGEHJP-UHFFFAOYSA-N boron;2-methylpyridine Chemical compound [B].CC1=CC=CC=N1 QHXLIQMGIGEHJP-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- HPXRVTGHNJAIIH-PTQBSOBMSA-N cyclohexanol Chemical group O[13CH]1CCCCC1 HPXRVTGHNJAIIH-PTQBSOBMSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 description 1
- 229950010133 enasidenib Drugs 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229950010738 ivosidenib Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- ORZHZQZYWXEDDL-UHFFFAOYSA-N methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol Chemical compound CS(O)(=O)=O.N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 ORZHZQZYWXEDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
- 125000005944 tetrahydroimidazopyridyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 208000016595 therapy related acute myeloid leukemia and myelodysplastic syndrome Diseases 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
本出願は、2019年5月31日に出願された、米国仮特許出願第62/855,619号の利益を主張するものであり、その開示はその全体が引用によって本明細書に援用される。
[式中、R1、R2、R3、R4、およびnは、本明細書に定義される通りである]
を有する化合物、またその薬学的に許容可能な塩、互変異性体、アイソトポログ、もしくは立体異性体が提供される。
定義
本明細書において用いられる用語「または」は、任意の1つまたは任意の組み合わせを意味する包括的な「または」として解釈されるべきである。そのため、「A、B、またはC」は以下のいずれかを意味する:「A;B;C;AおよびB;AおよびC;BおよびC;A、B、およびC」。この定義の例外は、要素、機能、手順、または行為の組み合わせが、本質的に相互に排他的である場合にのみ生じるであろう。
以下の式(I):
[式中、
R1は、C1-3アルキル、またはC1-3フルオロアルキルであり;
R2は、置換または非置換C1-6アルキル、置換または非置換C3-10シクロアルキル、置換または非置換3~6員ヘテロシクリル、置換または非置換C6-10アリール、または置換または非置換5~10員ヘテロアリールであり;
R3はHであり;
R4はハロゲンであり;
nは0~3である。]
を有する化合物、またはその薬学的に許容可能な塩、互変異性体、アイソトポログ、もしくは立体異性体が、本明細書に提供される。
イソインドリノンカルボキサミド化合物は、従来の有機合成および市販の出発物質を使用して製造することができる。限定ではなく例として、式(I)のイソインドリノンカルボキサミド化合物は、以下に示されるスキーム1および2、並びに本明細書に記載される実施例に概説されるように調製することができる。当業者は、例示的なスキームおよび実施例に記載される手順を修正して、目的の製品に到達する方法を知っているであろうことに留意されたい。
スキーム1に示されるように、式(I)のイソインドリノンカルボキサミド化合物[式中、R1、R2、R3、R4、およびnは、本明細書において定義されている通りである]は、ACN、THF、DCM、DMF、DMA、またはNMPなどの溶媒中で、DIPEA、TEA、またはNMMなどの塩基の存在下で、室温から約80℃の間の温度において、適切に誘導化した安息香酸アルキル[式中、HalはBrまたはIであり、RはC1-3アルキルである]を3-アミノピペリジン-2,6-ジオンと反応させて得ることができ、ハロゲン化 3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン中間体aが得られる。1,3-ビス(ジフェニルホスフィノ)プロパン、および酢酸パラジウムなどのパラジウム触媒の存在下、DMF、DMA、またはNMPなどの溶媒中、DIPEA、TEA、またはNMMなどの塩基の存在下、室温から約80℃の温度において、一酸化炭素および水による処理によって中間体をカルボニル化することによって、誘導化された2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボン酸b[式中、XはOHである]が生じる。中間体bはまた、2-MePyBH3、NaBH4、NaBH3CN、(CH3COO)3BHNa、またはデカボランなどの還元剤の存在下、ACN、MeOH、またはEtOHなどの溶媒中、酢酸または酢酸ナトリウムなどの酸の存在下で、適切に誘導化されたベンジルアルデヒド(式中、HalはBrまたはIである)を、3-アミノピペリジン-2,6-ジオンによって還元的アミノ化することによっても得ることができ、あるいは、ACN、MeOH、またはEtOHなどの溶媒中、酢酸または酢酸ナトリウムなどの酸の存在下で、二酸化炭素を取り除くことによって、中間体cが生じる。1,3-ビス(ジフェニルホスフィノ)プロパンおよび酢酸パラジウムなどのパラジウム触媒の存在下、DMF、DMA、またはNMPなどの溶媒中、DIPEA、TEA、またはNMMなどの塩基の存在下、室温および約80℃の間の温度において、中間体cを次いで、一酸化炭素および水で処理し、中間体bが生じる。別のアプローチにおいて、中間体cは、ACN、THF、DCM、DMF、DMA、またはNMPなどの溶媒中、DIPEA、TEA、またはNMMなどの塩基の存在下、室温から約80℃の間の温度において、適切に誘導体化したハロゲン化ベンジル(式中、HalはBrまたはIである)を3-アミノピペリジン-2,6-ジオンによって処理することによっても得ることができる。
式(I)の化合物[式中、R1、R2、R3、R4、およびnは本明細書において定義される通りであり]の別の合成方法は、スキーム2に示される。ジシクロヘキシル (3-ジシクロヘキシルホスファニウミルプロピル)ホスホニウム ジテトラフルオロボレートおよびパラジウム触媒、例えば、酢酸パラジウムの存在下、DMF、DMA、またはNMPなどの溶媒中で、DIPEA、TEA、NMM、K2CO3、またはNa2CO3などの塩基の存在下、室温から約80℃の間の温度で、適切に誘導体化した、カルボキシル保護5-アミノ-5-オキソ-4-(1-オキソイソインドリン-2-イル)ペンタン酸(式中、HalはBrまたはIであり、POはtert-ブチルなどのカルボキシル保護基である)を、一酸化炭素および水による処理によってカルボニル化し、中間体d[式中、XはOHである]を得る。DMF、DMA、DCM、THF、またはNMPなどの溶媒中、HOBT、EDCI、HATU、またはT3Pなどのカップリング剤、およびDIPEA、TEA、またはNMMなどの塩基の存在下、室温から約50℃の間の温度において、中間体dをアミンNH2(CR1R2R3)とカップリングさせて、カルボキシル保護された中間体eが生じる。脱保護および環化は、中間体eを、ACN、THF、DMF、DMA、またはNMPなどの溶媒中、室温から約80℃の間の温度において、ベンゼンスルホン酸、メタンスルホン酸、またはp-トルエンスルホン酸などの酸によって処理することによって達成され、式(I)の化合物[式中、R1、R2、R3、R4、およびnは、本明細書において定義される通りである]が生じる。
で示される化合物を調製するための方法であって、溶媒中、カップリング剤および塩基の存在下、適切な条件下で、式b:
[式中、XはOHである]
で示される化合物をNH2(CR1R2R3)と接触させて、式(I)の化合物を提供することを含む方法が本明細書において提供され、式中、
R1は、C1-3アルキル、またはC1-3フルオロアルキルであり;
R2は、置換または非置換C1-6アルキル、置換または非置換C3-10シクロアルキル、置換または非置換3~6員ヘテロシクリル、置換または非置換C6-10アリール、または置換または非置換5~10員ヘテロアリールであり;
R3は、Hであり;
R4は、ハロゲンであり;
nは0~3である。
で示される化合物を調製することを含み、当該方法は、1,3-ビス(ジフェニルホスフィノ)プロパンおよびパラジウム触媒の存在下、溶媒中、塩基の存在下、適切な条件下で、式c:
[式中、HalはBrまたはIである。]
で示される化合物を、一酸化炭素および水と接触させて、式bの化合物を提供することを含む。
で示される化合物を調製することを含み、当該方法は、溶媒中、塩基の存在下、適切な条件下で、式:
で示されるハロゲン化ベンジルを、3-アミノピペリジン-2,6-ジオンと接触させて、式cで示される化合物を提供することを含む。
で示される化合物を調製することを含み、当該方法は、還元剤の存在下、溶媒中、酸の存在下、適切な条件下で、式:
[式中、HalはBrまたはIである]
で示されるベンジルアルデヒドを、3-アミノピペリジン-2,6-ジオンと接触させて、式cで示される化合物を提供することを含む。
で示される化合物を調製することを含み、当該方法は、1,3-ビス(ジフェニルホスフィノ)プロパンおよびパラジウム触媒の存在下、溶媒中、塩基の存在下、適切な条件下で、式a:
[式中、HalはBrまたはIである]
で示される化合物を一酸化炭素および水と接触させて、式bの化合物を提供することを含む。
で示される化合物を調製することを含み、当該方法は、溶媒中、塩基の存在下、適切な条件下で、式:
[式中、HalはBrまたはIであり、RはC1-3アルキルである]
で示される安息香酸アルキルを、3-アミノピペリジン-2,6-ジオンと接触させて、式aの化合物を提供することを含む。
で示される化合物を調製する方法であって、溶媒中、適切な条件下で、式e:
[式中、POはカルボキシル保護基である。]
で示される化合物を、酸と接触させて、式(I)の化合物を提供することを含む方法が本明細書において提供され、式中、
R1は、C1-3アルキル、またはC1-3フルオロアルキルであり;
R2は、置換または非置換C1-6アルキル、置換または非置換C3-10シクロアルキル、置換または非置換3~6員ヘテロシクリル、置換または非置換C6-10アリール、または置換または非置換5~10員ヘテロアリールであり;
R3は、Hであり;
R4は、ハロゲンであり;
nは0~3である。
で示される化合物を調製することを含み、当該方法は、溶媒中、カップリング剤および塩基の存在下、適切な条件下で、式d:
[式中、XはOHである]
で示される化合物をNH2(CR1R2R3)と接触させて、式eで示される化合物を提供することを含む。
で示される化合物を調製することを含み、当該方法は、ジシクロヘキシル (3-ジシクロヘキシルホスファニウミルプロピル)ホスホニウム ジテトラフルオロボラートおよびパラジウム触媒の存在下、溶媒中、塩基の存在下、適切な条件で、式:
[式中、HalはBrまたはIである]
で示される化合物を、一酸化炭素および水と接触させて、式dで示される化合物を提供することを含む。
イソインドリノンカルボキサミド化合物は、動物またはヒトの病状を治療、予防、または改善するための医薬としての有用性を有する。したがって、イソインドリノンカルボキサミド化合物、または以下に記載される疾患の治療または予防などの医薬として使用するための、イソインドリノンカルボキサミド化合物を含む医薬組成物が本明細書において提供される。本明細書において提供される方法は、有効量の1つ以上のイソインドリノンカルボキサミド化合物を、必要な対象に投与することを含む。
イソインドリノンカルボキサミド化合物は、従来の製剤の形態、例えば、カプセル、マイクロカプセル、錠剤、顆粒、散剤、トローチ、丸剤、坐薬、注射剤、懸濁液、シロップ、パッチ、クリーム、ローション、軟膏、ゲル、スプレー、溶液、およびエマルジョンなどにおいて、経口的、局所的、または非経口的に対象に投与されうる。適切な製剤は、従来の有機または無機添加剤、例えば、賦形剤(例えば、スクロース、デンプン、マンニトール、ソルビトール、ラクトース、グルコース、セルロース、タルク、リン酸カルシウム、または炭酸カルシウム)、結合剤(例えば、セルロース、メチルセルロース、ヒドロキシメチルセルロース、ポリプロピルピロリドン、ポリビニルピロリドン、ゼラチン、アラビアゴム、ポリエチレングリコール、スクロース、またはデンプン)、崩壊剤(例えば、デンプン、カルボキシメチルセルロース、ヒドロキシプロピルデンプン、低置換ヒドロキシプロピルセルロース、重炭酸ナトリウム、リン酸カルシウム、またはクエン酸カルシウム)、滑沢剤(例えば、ステアリン酸マグネシウム、軽質無水ケイ酸、タルク、またはラウリル硫酸ナトリウム)、香料(例えば、クエン酸、メントール、グリシン、またはオレンジ色粉末)、防腐剤(例えば、安息香酸ナトリウム、亜硫酸水素ナトリウム、メチルパラベン、またはプロピルパラベン)、安定化剤(例えば、クエン酸、クエン酸ナトリウム、または酢酸)、懸濁化剤(例えば、メチルセルロース、ポリビニルピロリドン、またはステアリン酸アルミニウム)、分散剤(例えば、ヒドロキシプロピルメチルセルロース)、希釈剤(例えば、水)、および基剤ワックス(例えば、カカオバター、白色ワセリン、またはポリエチレングリコール)を一般的に用いる方法によって、製造することができる。医薬組成物中のイソインドリノンカルボキサミド化合物の有効量は、目的の効果を発揮する分量;例えば、経口投与および非経口投与の両方について、単位用量において、約0.005mg/対象体重kgから約10mg/対象体重kgでありうる。
実施例2:N-((S)-1-シクロヘキシルエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例3:2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((S)-1-フェニルプロピル)イソインドリン-5-カルボキサミド
実施例4:N-((R)-1-シクロヘキシルエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例5:N-((R)-1-シクロヘキシル-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例6:2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-フェニルエチル)イソインドリン-5-カルボキサミド
実施例7:2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((S)-3,3,3-トリフルオロ-1-フェニルプロピル)イソインドリン-5-カルボキサミド
実施例8:2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-(4-フルオロフェニル)エチル)イソインドリン-5-カルボキサミド
実施例9:2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-(ピリジン-2-イル)エチル)イソインドリン-5-カルボキサミド
実施例10:2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-(ピリジン-3-イル)エチル)イソインドリン-5-カルボキサミド
実施例11および12:2-((R)-2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-フェニルエチル)イソインドリン-5-カルボキサミドおよび2-((S)-2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-フェニルエチル)イソインドリン-5-カルボキサミド
実施例13:2-(2,6-ジオキソピペリジン-3-イル)-6-フルオロ-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-フェニルエチル)イソインドリン-5-カルボキサミド
実施例14:2-(2,6-ジオキソピペリジン-3-イル)-4-フルオロ-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-フェニルエチル)イソインドリン-5-カルボキサミド
実施例15および16:2-((S)-2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-(4-フルオロフェニル)エチル)イソインドリン-5-カルボキサミドおよび2-((R)-2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-(4-フルオロフェニル)エチル)イソインドリン-5-カルボキサミド
実施例17:N-((R)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例18:N-((R)-1-(5-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例19:2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-(3-フルオロピリジン-2-イル)エチル)イソインドリン-5-カルボキサミド
実施例20:N-((R)-1-(5-クロロ-3-フルオロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例21:N-((R)-1-(3,5-ジフルオロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例22:4-クロロ-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-(4-フルオロフェニル)エチル)イソインドリン-5-カルボキサミド
実施例23:2-(2,6-ジオキソピペリジン-3-イル)-N-((S)-2-メチル-1-フェニルプロピル)-1-オキソイソインドリン-5-カルボキサミド
実施例24:N-((R)-1-(2-シクロプロポキシフェニル)-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例25および26:N-((R)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((S)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミドおよびN-((R)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((R)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例27.N-((R)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((S)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミドの代替合成
実施例28:N-((R)-1-(3,5-ジフルオロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例29:N-((R)-1-(3,5-ジクロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例30:N-((R)-1-(5-クロロ-3-フルオロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((S)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
実施例31:N-((R)-1-(3-クロロ-5-((ジメチルアミノ)メチル)ピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド ヒドロクロライド
実施例32:2-(2,6-ジオキソピペリジン-3-イル)-1-オキソ-N-((R)-2,2,2-トリフルオロ-1-(2-モルホリノフェニル)エチル)イソインドリン-5-カルボキサミド
実施例33:N-((R)-1-(3,5-ジクロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((S)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミド
アッセイ
CK1α分解アッセイ
y=(A+((B-A)/(1+((C/x)^D))))
A=YMin(カーブフィッティングによって決定される、化合物処理に応答する、DMSO対照に対して標準化した最低CK1α量)
B=YMax(DMSO対照におけるCK1α量)
C=EC50
D=ヒルの勾配
x=化合物濃度
EC50=y=(YMax-YMin)/2のときの化合物の濃度
DC50=y=DMSO対照の50%(50%CK1α分解)のときの化合物の濃度
y=DMSO対照に対して標準化したCK1αタンパク質量
細胞に基づくアッセイ
y=(A+((B-A)/(1+((C/x)^D))))
[式中、
A=YMin
B=YMax
C=EC50
D=ヒル勾配
IC50=YがDMSO対照の50%である場合の化合物の濃度
Y=発光ユニットとして測定される、細胞生存率、および
x=化合物の濃度]
インビボアッセイ
活性表
Claims (43)
- R1が、メチル、エチル、n-プロピル、イソプロピル、CH2F、CHF2、CF3、CH2CH2F、CH2CHF2、CH2CF3、CHFCH3、CF2CH3、またはCF2CF3である、請求項1~11のいずれか1項に記載の化合物。
- R1が、メチル、エチル、イソプロピル、CHF2、CF3、CH2CF3、またはCF2CH3である、請求項1~12のいずれか1項に記載の化合物。
- R2が、ハロゲン、CN、OR’、置換または非置換C1-3アルキル、および置換または非置換-(C0-3アルキル)(3~6員ヘテロシクリル)から選択される1つ以上の置換基で置換され;R’が、それぞれ独立して、H、置換または非置換C1-3アルキル、置換または非置換C3-6シクロアルキル、およびフェニルから選択される、請求項1~13のいずれか1項に記載の化合物。
- R2が、F、Cl、Br、CN、OH、OCH3、OCF3、OCH2CH3、O-n-プロピル、O-イソプロピル、O-n-ブチル、O-sec-ブチル、O-tert-ブチル、O-シクロプロピル、O-シクロブチル、O-フェニル、CH3、CH2CH3、CF3、CH2CF3、CH2NHCH3、CH2N(CH3)2、並びにピペリジル、ピペラジニル、モルホリノ、CH2-アジリジル、CH2-ピロリジル、CH2-ピペラジニル、CH2-ピペリジル、CH2-モルホリニル、およびCH2(2-オキサ-6-アザスピロ[3.3]ヘプチル)から選択される-(C0-3アルキル)(3~6員ヘテロシクリル)から選択される1つ以上の置換基で置換され、-(C0-3アルキル)(3~6員ヘテロシクリル)が適宜、1つ以上のF、Cl、またはCH3で置換されている、請求項1~14のいずれか1項に記載の化合物。
- R2が、F、Cl、CN、OH、OCH3、OCF3、O-イソプロピル、O-シクロプロピル、O-フェニル、CH3、CF3、CH2CF3、CH2N(CH3)2、並びにモルホリノ、ピペラジニル、CH2-アジリジル、CH2-ピロリジル、CH2-ピペラジニル、CH2-モルホリニル、およびCH2(2-オキサ-6-アザスピロ[3.3]ヘプチル)から選択される-(C0-3アルキル)(3~6員ヘテロシクリル)から選択される、1つ以上の置換基で置換され、-(C0-3アルキル)(3~6員ヘテロシクリル)が適宜、1つ以上のFまたはCH3で置換されている、請求項1~15のいずれか1項に記載の化合物。
- R2が、非置換、またはハロゲン、CN、およびOR’から独立して選択される1つ以上の置換基で置換されている、C1-6アルキル;非置換、またはハロゲン、OR’、および置換または非置換C1-3アルキルから独立して選択される1つ以上の置換基で置換されている、C3-10シクロアルキル;非置換、または1つ以上の置換または非置換C1-3アルキルで置換されている、3~6員ヘテロシクリル;非置換、またはハロゲン、CN、OR’、置換または非置換C1-3アルキル、および置換または非置換-(C0-3アルキル)(3~6員ヘテロシクリル)から独立して選択される、1つ以上の置換基によって置換されている、C6-10アリール;または、非置換、またはハロゲン、OR’、および置換または非置換C1-3アルキルから独立して選択される、1つ以上の置換基で置換されている、5~10員ヘテロアリールであり;R’がそれぞれ独立して、H、置換または非置換C1-3アルキル、置換または非置換C3-6シクロアルキル、およびフェニルから選択される、請求項1~16のいずれか1項に記載の化合物。
- R2が、非置換、またはF、CN、およびOHから独立して選択される1つ以上の置換基で置換されている、C1-6アルキルである、請求項1~13および17のいずれか1項に記載の化合物。
- R2が、CH3、イソプロピル、ter-ブチル、C(CH3)2CH2OH、C(CH3)2CN、またはC(CH3)2CF3である、請求項18に記載の化合物。
- R2が、非置換、またはF、OH、CH3、C(CH3)2OH、およびCF3から独立して選択される1つ以上の置換基で置換されている、C3-10シクロアルキルである、請求項1~13のいずれか1項に記載の化合物。
- R2が、シクロプロピル、シクロブチル、シクロペンチル、シクロヘキシル、スピロ[3.5]ノニル、ビシクロ[1.1.1]ペンチル、またはスピロ[2.5]オクチルである、請求項20に記載の化合物。
- R2が、非置換、または1つ以上のCH3、およびCH2CF3で置換されている、3~6員ヘテロシクリルである、請求項1~13のいずれか1項に記載の化合物。
- R2が、オキセタニル、テトラヒドロピラニル、またはピペリジルである、請求項22に記載の化合物。
- R2が、非置換、またはF、Cl、CN、OH、OCH3、OCF3、O-イソプロピル、O-シクロプロピル、O-フェニル、CH3、CF3、およびCH2N(CH3)2から独立して選択される1つ以上の置換基によって置換されている、C6-10アリール;およびピペラジニル、モルホリノ、CH2-アジリジル、CH2-ピロリジル、CH2-ピペラジニル、CH2-モルホリニル、およびCH2(2-オキサ-6-アザスピロ[3.3]ヘプチル)から選択される、-(C0-3アルキル)(3~6員ヘテロシクリル)であり、-(C0-3アルキル)(3~6員ヘテロシクリル)は、1つ以上のF、またはCH3によって適宜置換されている、請求項1~13のいずれか1項に記載の化合物。
- R2がフェニルである、請求項24に記載の化合物。
- R2が、非置換、またはF、Cl、OCH3、CH3、CF3、およびCH2N(CH3)2から独立して選択される1つ以上の置換基で置換されている、5~10員ヘテロアリールである、請求項1~13のいずれか1項に記載の化合物。
- R2が、ピラゾリル、ピリジル、ピラジニル、またはピリミジルである、請求項1~13および26のいずれか1項に記載の化合物。
- R4が、FまたはClである、請求項1~27のいずれか1項に記載の化合物。
- nが、0、1、または2である、請求項1~28のいずれか1項に記載の化合物。
- 表1から選択される化合物、またはその薬学的に許容可能な塩、互変異性体、アイソトポログ、もしくは立体異性体。
- 有効量の請求項1~30のいずれか1項に記載の化合物、またはその薬学的に許容可能な塩、互変異性体、アイソトポログ、もしくは立体異性体、および薬学的に許容可能な担体、賦形剤、または溶媒を含む、医薬組成物。
- 急性骨髄性白血病を治療または予防する方法であって、それを必要とする対象に、有効量の請求項1~30のいずれか1項に記載の化合物を投与することを含む、方法。
- 急性骨髄性白血病を治療または予防する方法であって、それを必要とする対象に、有効量の請求項31に記載の医薬組成物を投与することを含む、方法。
- 急性骨髄性白血病が、新たに診断された急性骨髄性白血病である、請求項32~33のいずれか1項に記載の方法。
- 急性骨髄性白血病が再発性、難治性、または従来の治療に耐性である、請求項32~33のいずれか1項に記載の方法。
- CK1αタンパク質レベルを低下させる方法であって、細胞を有効量の請求項1~30のいずれか1項に記載の化合物と接触させることを含む方法。
- 細胞が対象に存在する、請求項36に記載の方法。
- 医薬として使用するための、請求項1~30のいずれか1項に記載の化合物、または請求項31に記載の医薬組成物。
- 急性骨髄性白血病を治療または予防するための方法であって、有効量の化合物を必要な対象に投与することを含む方法において用いるための、請求項1~30のいずれか1項に記載の化合物。
- 急性骨髄性白血病を治療または予防するための方法であって、有効量の医薬組成物を必要な対象に投与することを含む方法において使用するための、請求項31に記載の医薬組成物。
- 急性骨髄性白血病が、新たに診断された急性骨髄性白血病である、請求項39に記載の使用のための化合物、または請求項40に記載の使用のための医薬組成物。
- 急性骨髄性白血病が、再発性、難治性、または従来の治療に耐性である、請求項39に記載の使用のための化合物、または請求項40に記載の使用のための医薬組成物。
- エクスビボまたはインビトロで細胞内のCK1αタンパク質量を低下させる方法であって、細胞を有効量の請求項1~30のいずれか1項に記載の化合物と接触させることを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855619P | 2019-05-31 | 2019-05-31 | |
US62/855,619 | 2019-05-31 | ||
PCT/US2020/035043 WO2020243379A1 (en) | 2019-05-31 | 2020-05-29 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022534979A true JP2022534979A (ja) | 2022-08-04 |
JPWO2020243379A5 JPWO2020243379A5 (ja) | 2023-05-30 |
JP7496838B2 JP7496838B2 (ja) | 2024-06-07 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
US20200377512A1 (en) | 2020-12-03 |
MX2021014350A (es) | 2022-02-21 |
AU2020282748A1 (en) | 2021-12-09 |
IL288278A (en) | 2022-01-01 |
EP3976595A4 (en) | 2023-01-04 |
US11306101B2 (en) | 2022-04-19 |
CN114957212A (zh) | 2022-08-30 |
CO2021015624A2 (es) | 2022-02-28 |
AR119057A1 (es) | 2021-11-17 |
CL2021003134A1 (es) | 2022-07-01 |
SG11202112872YA (en) | 2021-12-30 |
KR20220016167A (ko) | 2022-02-08 |
PE20220569A1 (es) | 2022-04-20 |
CA3136753A1 (en) | 2020-12-03 |
EP3976595A1 (en) | 2022-04-06 |
TW202110819A (zh) | 2021-03-16 |
US20220213115A1 (en) | 2022-07-07 |
BR112021022758A2 (pt) | 2022-03-22 |
CN114269729A (zh) | 2022-04-01 |
WO2020243379A1 (en) | 2020-12-03 |
CN114957212B (zh) | 2024-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11306101B2 (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
JP7458324B2 (ja) | 置換された4-アミノイソインドリン-1,3-ジオン化合物、及びリンパ腫の治療のためのそれらの使用 | |
JP6779870B2 (ja) | 抗増殖性化合物及びその使用方法 | |
US11873283B2 (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
EP3897631A1 (en) | Targeted protein degradation | |
MX2010014002A (es) | Compuestos de triazolopiridina inhibidores de jak y los metodos. | |
EP3806958B1 (en) | 6-aminopyridin-3-yl pyrazoles as modulators of roryt | |
JP7492962B2 (ja) | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療法 | |
WO2018234978A1 (en) | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | |
WO2021262810A1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
JP2023531709A (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
EP4304591A1 (en) | Pharmaceutical composition for the treatment of alzheimer's disease or dementia | |
JP7496838B2 (ja) | 置換1-オキソ-イソインドリン-5-カルボキサミド化合物、その組成物、およびそれによる治療方法 | |
WO2023176554A1 (ja) | 認知機能改善剤 | |
JP2024073590A (ja) | 置換された4-アミノイソインドリン-1,3-ジオン化合物、及びリンパ腫の治療のためのそれらの使用 | |
CN117545752A (zh) | Cereblon结合化合物、其组合物及其用于治疗的方法 | |
KR20240025613A (ko) | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 | |
CA3237015A1 (en) | Heterobifunctional compounds as hpk1 degraders | |
WO2024102706A1 (en) | Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20220307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230519 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230519 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240425 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |